Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsWilliam Querbes, Kevin Fitzgerald, Brian Bettencourt, Abigail Liebow, David V. Erbe
Life of this patent
Estimating the term…
Abstract
The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the HAO1 gene, and methods of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1.
Claims34
A double stranded RNAi agent that inhibits expression of HAO1 in a cell, or a salt thereof,
- wherein said double stranded RNAi agent or a salt thereof, comprises a sense strand and an antisense strand forming a double-stranded region,
- wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequences of SEQ ID NO:1 SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:6 and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequences of SEQ ID NO:3 SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO:8;
- wherein all of the nucleotides of said sense strand and all of the nucleotides of said antisense strand comprise a nucleotide modification, and
- wherein at least one strand is conjugated to a ligand.
(canceled)
(canceled)
-17. (canceled)
-23. (canceled)
-27. (canceled)
-40. (canceled)
-55. (canceled)
A double stranded RNAi agent that inhibits expression of HAO1 in a cell, or a salt thereof,
- wherein said double stranded RNAi agent, or a salt thereof, comprises a sense strand and an antisense strand forming a double stranded region,
- wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequences of from any one of the nucleotide sequences of SEQ ID NO:1 SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:6 and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequences of SEQ ID NO:3 SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO:8,
- wherein all of the nucleotides of said sense strand comprise a modification selected from the group consisting of a 2′-O-methyl modification and a 2′-fluoro modification,
- wherein said sense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus,
- wherein all of the nucleotides of said antisense strand comprise a modification selected from the group consisting of a 2′-O-methyl modification and a 2′-fluoro modification,
- wherein said antisense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus and two phosphorothioate internucleotide linkages at the 3′-terminus, and
- wherein said sense strand is conjugated to one or more GalNAc derivatives attached through a branched bivalent or trivalent linker at the 3′-terminus.
-66. (canceled)
-73. (canceled)
-81. (canceled)
(canceled)
(canceled)
-89. (canceled)
The method of claim 87, wherein the double stranded RNAi agent or a salt thereof, is administered to the subject subcutaneously.
-94. (canceled)
Dependencies are inferred from the claim text.